These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 9007709)

  • 1. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study.
    Flichman D; Colombatto P; Randone A; Baldi M; Bellati G; Negro F; Oliveri F; Colucci G; Verme G; Bonino F; Brunetto MR
    Clin Diagn Virol; 1997 May; 8(1):63-70. PubMed ID: 9248659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.
    Marcellin P; Boyer N; Gervais A; Martinot M; Pouteau M; Castelnau C; Kilani A; Areias J; Auperin A; Benhamou JP; Degott C; Erlinger S
    Ann Intern Med; 1997 Nov; 127(10):875-81. PubMed ID: 9382365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
    Shindo M; Arai K; Okuno T
    J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.
    Fargion S; Fracanzani AL; Sampietro M; Molteni V; Boldorini R; Mattioli M; Cesana B; Lunghi G; Piperno A; Valsecchi C; Fiorelli G
    Eur J Gastroenterol Hepatol; 1997 May; 9(5):497-503. PubMed ID: 9187884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies.
    Calleja JL; Albillos A; Cacho G; Iborra J; Abreu L; Escartín P
    J Hepatol; 1996 Mar; 24(3):308-12. PubMed ID: 8778197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C.
    Kakumu S; Aiyama T; Okumura A; Iwata K; Ishikawa T; Yoshioka K
    J Gastroenterol Hepatol; 1997 Jun; 12(6):468-72. PubMed ID: 9195406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.
    Aiyama T; Yoshioka K; Hirofuji H; Kusakabe A; Yamada M; Tanaka K; Kakumu S
    Dig Dis Sci; 1994 Oct; 39(10):2244-9. PubMed ID: 7924750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.
    Brouwer JT; Hansen BE; Niesters HG; Schalm SW
    J Hepatol; 1999 Feb; 30(2):192-8. PubMed ID: 10068095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of relapses after interferon-alpha therapy by hepatitis C virus RNA in peripheral blood mononuclear cells.
    Kusaka S; Okusa T; Araki A; Fujiki K; Takashimizu I; Okayasu I; Yamamoto N; Sato C
    J Med Virol; 1995 Jul; 46(3):265-8. PubMed ID: 7561801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
    Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
    J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy.
    Bekkering FC; Brouwer JT; Leroux-Roels G; Van Vlierberghe H; Elewaut A; Schalm SW
    J Hepatol; 1998 Jun; 28(6):960-4. PubMed ID: 9672170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
    Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
    J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment.
    Orito E; Mizokami M; Suzuki K; Ohba KI; Ohno T; Mizuno M; Iijima Y; Saito H; Nemoto A; Nukuta N
    J Gastroenterol Hepatol; 1997 Jan; 12(1):58-61. PubMed ID: 9076625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (southern Italy).
    Magrin S; Craxi A; Fabiano C; Marino L; Fiorentino G; Lo Iacono O; Volpes R; Di Marco V; Almasio P; Vaccaro A; Urdea MS; Wilber JC; Bonura C; Gianguzza F; Capursi V; Filiberti S; Stuyver L; Pagliaro L
    J Hepatol; 1996 Nov; 25(5):583-90. PubMed ID: 8938531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
    Bell H; Hellum K; Harthug S; Maeland A; Ritland S; Myrvang B; von der Lippe B; Raknerud N; Skaug K; Gutigard BG; Skjaerven R; Prescott LE; Simmonds P
    Scand J Infect Dis; 1997; 29(1):17-22. PubMed ID: 9112292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.